PeptideStack
5.2kquestions
20kanswers
220users

Does splitting a 60 mg weekly dose of cagrilintide across two administrations change anything?

Asked 7 Sept 2025Modified 8 months agoViewed 11k times
10

Setup, so nobody has to ask: 60 mg · cagrilintide.

I keep seeing this stated as a fact with no explanation attached, and unexplained facts make me suspicious.

My background is quantitative but not chemical, so I can follow an equation more easily than a hand-wave.

Is the standard explanation correct, and if so, what is the evidence for it?

split-dosing
split-dosing

Dividing a weekly dose across more than one administration. Questions here concern the pharmacokinetic rationale, whether the peak-to-trough ratio…

39 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

811 questions
glp1-mechanism
glp1-mechanism

Receptor-level pharmacology: GLP-1R as a class B GPCR, cAMP and PKA signalling, biased agonism, internalisation and resensitisation, and the…

175 questions
shareeditfollowflag
WO
askedw_okoye40k1387 Sept 2025

2 Answers

Sorted by votes
44

The distinction that resolves most of these questions is understanding what concentration actually means and why it is not the same as label claim.

Dead space quantified: a fixed-needle insulin syringe holds roughly 3 to 5 µL in the hub and needle after the plunger bottoms out. A luer-lock syringe with a detachable needle holds 35 to 100 µL depending on the hub design. At 5 mg/mL that is 15 to 25 µg lost per draw on the insulin syringe and 175 to 500 µg on the luer-lock — which over ten draws is the difference between losing a rounding error and losing half a milligram.

Rotation of injection site is a tolerability measure, not a pharmacokinetic one, but if you are going to do it you might as well do it right.

Published data on syringe dead space quantifies low-dead-space designs as retaining under 2 µL against 35 µL or more for conventional detachable-needle syringes.

If in doubt, use more diluent and accept the shorter usable window.

shareimprove this answerflag
DC
answereddrawn_and_capped15k2810 Nov 2025
3This matches what I was told by a laboratory, for whatever that is worth. – forty_two_c 2 months ago
2Minor: the trial name is hyphenated in the original publication. – tandem_gradient 9 days ago
add a comment
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
29

Put another way, the arithmetic only stops being confusing once you work it through once and see that it is straightforward.

Do not use the same needle to pierce the stopper and to administer. The tip is blunted by the stopper, and the hub now contains a dose you are about to lose to dead space anyway.

The concentration you actually work with is label claim times content fraction divided by actual diluent volume, which is usually not the same as the nominal concentration because content is usually not 100 per cent and you rarely measure the diluent volume to 0.1 mL precision.

Write the arithmetic on the vial label. It costs nothing and removes the step where you reconstruct it from memory.

shareimprove this answerflag
CF
answeredclaudia_ferrante46k3821 Nov 2025
2Good answer, but the confidence interval in the cited trial is wider than implied. – cake_collapsed 2 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.